High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer

The objective of this phase I/II trial is to prospectively evaluate the toxicity and therapeutic efficacy of Stereostatic Body Radiation Therapy (SBRT) to prostate and pelvic lymph nodes in combination with high-dose-rate (HDR) brachytherapy to the prostate in patients with localized unfavorable-intermediate risk or higher disease.

Trial Details

NCT ID
NCT05754580
Phase
NA
Sponsor
University of Nebraska
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • High Dose Brachytherapy
  • Stereostatic Body Radiation Therapy
Locations (sample)
  • Omaha, Nebraska, United States|41.25626,-95.94043

Key Eligibility Criteria

  • Histopathologically proven diagnosis of local unfavorable intermediate or higher risk prostate cancer as defined by NCCN risk group criteria. Biops…
  • No prior definitive treatment or intervention received.
  • Life expectancy of more than 10 years as estimated by the treating physician.
  • Negative evaluation lymph node involvement or distant metastatic disease on abdominopelvic CT, prostate MRI, and/or PSMA PET.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →